Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.

about

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q48172134

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Randomized study of etirinotec ...... metastatic colorectal cancer.

@en

Randomized study of etirinotec ...... metastatic colorectal cancer.

@nl

type

Item

label

Randomized study of etirinotec ...... metastatic colorectal cancer.

@en

Randomized study of etirinotec ...... metastatic colorectal cancer.

@nl

prefLabel

Randomized study of etirinotec ...... metastatic colorectal cancer.

@en

Randomized study of etirinotec ...... metastatic colorectal cancer.

@nl

P1476

Randomized study of etirinotec ...... r metastatic colorectal cancer

@en

P2093

Alison L Hannah

http://www.w3.org/2001/XMLSchema#string

Kalyan Mukherjee

http://www.w3.org/2001/XMLSchema#string

Mark Saunders

http://www.w3.org/2001/XMLSchema#string

Mary Tagliaferri

http://www.w3.org/2001/XMLSchema#string

Maurice Berkowitz

http://www.w3.org/2001/XMLSchema#string

Philip Philip

http://www.w3.org/2001/XMLSchema#string

Shailesh Bondarde

http://www.w3.org/2001/XMLSchema#string

Tatjana Kolevska

http://www.w3.org/2001/XMLSchema#string

Tracy Dobbs

http://www.w3.org/2001/XMLSchema#string

Ute Hoch

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.

Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.

A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

A review of the evolution of systemic chemotherapy in the management of colorectal cancer.

P2888

s00280-017-3438-y

P304

1161-1169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3438-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Leslie Samuel

Heinz-Josef Lenz

P577

2017-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29043412

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

6863159

http://www.w3.org/2001/XMLSchema#string